Therefore, this study aimed to examine whether various patient pretreatment factors, including serum albumin levels, are associated with long-term survival beyond 2 years in patients with R/M HNSCC treated with nivolumab. The gene discussed is ALB; the disease is head and neck squamous cell carcinoma.